Evolution of therapies for chronic myelogenous leukemia. - Wikidata - awgldk - TriplyDB

Evolution of therapies for chronic myelogenous leukemia.

Evolution of therapies for chronic myelogenous leukemia.

http://www.wikidata.org/entity/Q37966915

about

Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation Bosutinib: a novel src/abl kinase inhibitor for chronic myelogenous leukemia.Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.Mechanisms of action and resistance for multiple myeloma novel drug treatments.The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.Genomic instability in chronic myeloid leukemia: targets for therapy?Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

P2860

Q26768158-FA6D15B4-2712-4833-907B-23CBD0F1CEAF Q33414445-9C31D1D2-2F53-46DA-AE0B-D15DE6292579 Q34563073-0670AA13-61EE-4153-A056-0482B232A9E1 Q35106637-717C740B-822B-4358-9490-5D301AEED5A1 Q36926106-A0C2F39C-1CD1-4346-B8A1-F68612394693 Q37051682-5CC64B29-5394-443C-8F55-3DD9E01DB997 Q37682119-FE341F20-ABBC-4136-9621-9F677062EA3B Q38230432-AEC709FD-540C-42CC-B041-A67F07740173 Q38289046-93090F23-294F-442A-959B-A704446F0080 Q38860769-A3735306-B615-47E0-9ACA-8F9DA0AD1455 Q40151542-5728662C-1634-43D6-BB80-508A05913A87 Q41134308-4C16D87A-CD87-4151-B8B6-183DC84A2A21 Q42125187-8CE944C5-DD35-4015-B66F-451B957C7C88 Q42694880-C7E5B6B3-9205-4798-9315-C353F075EB2D Q47216949-F5DA33FF-578D-4FE5-917B-96FA66BA0130 Q50916805-A23742AE-C1B5-406F-8327-9049778D7EC0 Q53020461-5A61CEDE-ADD7-4490-A06F-5A07317B9BFA Q53272675-64E494B9-EF8B-4BC9-BD5C-475D0FED35D8 Q58761411-8CBCFA29-1D92-4733-A548-165A3FDD1E86

P2860

Evolution of therapies for chronic myelogenous leukemia.

http://www.wikidata.org/entity/Q37966915

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Evolution of therapies for chronic myelogenous leukemia.

@en

Evolution of therapies for chronic myelogenous leukemia.

@nl

type

label

Evolution of therapies for chronic myelogenous leukemia.

@en

Evolution of therapies for chronic myelogenous leukemia.

@nl

prefLabel

Evolution of therapies for chronic myelogenous leukemia.

@en

Evolution of therapies for chronic myelogenous leukemia.

@nl

P1433

Q37966915-E7852194-5831-4E33-B588-882D69C2D98A

P1476

Q37966915-FF5D3C22-CD52-454E-A819-3E3D93BD4878

P2093

Q37966915-824212CA-E125-4E98-B8B9-C5E337070D3E

Q37966915-A5AE621B-0660-405A-B829-E046347ED5D8

P2860

Q37966915-00EEDCBE-AC2A-4C02-AA26-CC12CB111F58

Q37966915-04B4AD07-6D46-427E-8956-3419447D1D7A

Q37966915-08E52AA4-2C3F-4D93-8902-46193084E699

Q37966915-0A878BA4-A504-44F3-893B-6CFD268F6B76

Q37966915-0BA3F555-7AB7-4AE7-9867-491C766CFC21

Q37966915-1249D56D-6900-45E1-A1BB-88595BD8B84B

Q37966915-1C495F87-8511-4BB5-A2FB-93B16E5B8CB2

Q37966915-1CDF1945-CBBB-4A7D-BFB9-53424B3F2379

Q37966915-251FD1EC-80F9-4BB4-94EC-B96A647848D0

Q37966915-2DF22364-0267-4DB0-8E49-7E466D7DD8F2

P304

Q37966915-FAB6FB77-8CAC-4588-A9AA-768730BB6CD6

P31

Q37966915-700BB765-F8F1-40CB-8402-67248CF49672

P356

Q37966915-18848DF8-4045-494D-A63D-8CAD15F4831C

P433

Q37966915-AE37FF90-B540-4440-AB54-186C33705007

P478

Q37966915-08650513-CC88-470C-83AF-8CD6FB266D62

P50

Q37966915-197A2415-4E70-4775-A52A-828B37AF88F4

Q37966915-90DFF864-8C8A-4C0D-87B2-15CF8828FF40

P577

Q37966915-55035731-F626-49C9-AAC1-156E3926E3A0

P5875

Q37966915-20FFBF6F-8F61-4ECB-B9F7-5B6DE4CA9083

P698

Q37966915-EB7CC2B9-96D9-4C0E-AF15-BC46E664BCA9

P921

Q37966915-8977274B-278A-498F-BE6D-330AA062D9DE

P932

Q37966915-BC9198A0-2EE5-447D-9DFD-A44F71F44EA8

P356

PPO.0B013E31823DEC8D

P1433

The Cancer Journal

P1476

Evolution of therapies for chronic myelogenous leukemia.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Fabio P S Santos

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

P304

465-476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PPO.0B013E31823DEC8D

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51867410

http://www.w3.org/2001/XMLSchema#string

P698

22157290

http://www.w3.org/2001/XMLSchema#string

P921

P932

3243359

http://www.w3.org/2001/XMLSchema#string